/
/
CAR T Dosing and Enrollment Increase Changes Made in Celgene/Bluebird KarMMa Study
CAR T Dosing and Enrollment Increase Changes Made in Celgene/Bluebird KarMMa Study image
CAR T Dosing and Enrollment Increase Changes Made in Celgene/Bluebird KarMMa Study
Posted Jul 13, 2018

Celgene has amended the protocol of the Phase II KarMMa study to increase the dose and number of patients to be enrolled for the CAR T bb2121 treatment. The study is currently open for relapsed/refractory multiple myeloma. 

Based on prior data, the dose in the Phase II study has been increased to 15 - 45 x 10CAR T-cells from 15 - 30 x 10cells. The study will enroll up to 140 patients.  

The Phase I study (called CRB-401) will also increase enrollment to an additional 20 patients and the dose range will be the same as the KarMMa study. 

Celgene and bluebird bio anticipate regulatory approval for bb2121 for multiple myeloma in 2020. 

 

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811